| Literature DB >> 7764460 |
Abstract
Multidrug resistance (MDR) is a major problem in cancer chemotherapy. As P-glycoprotein is the key molecule in MDR, many investigators have constructed anti-P-glycoprotein monoclonal antibodies (MAbs). Those antibodies, including MRK16 and C219, were used for elucidation of the mechanism of MDR and for overcoming of MDR. This article describes the characterization of the antibodies against the P-glycoprotein and other proteins of multidrug-resistant tumor cells, and discusses the therapeutic implication of the antibodies.Entities:
Mesh:
Substances:
Year: 1993 PMID: 7764460 DOI: 10.1007/BF00744659
Source DB: PubMed Journal: Cytotechnology ISSN: 0920-9069 Impact factor: 2.058